Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274443 | 0.74 | ERN1 (0.34) | ERN1 | |
| SCHEMBL660833 | 0.73 | ERN1 (0.33) | ERN1 | |
| SCHEMBL30127235 | 0.73 | PRKDC (0.33) | — | |
| SCHEMBL15748351 | 0.71 | ERN1 (0.38) | ERN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL658249 | 0.70 | CYP2C9 (0.41) | ERN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29471351 | 0.70 | CYP2C9 (0.41) | ERN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30826192 | 0.70 | ERN1 (0.36) | ERN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL660309 | 0.70 | ERN1 (0.37) | ERN1 | |
| SCHEMBL658069 | 0.69 | CYP2A6 (0.38) | ERN1 | |
| SCHEMBL28953827 | 0.68 | PRKDC (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | ERN1 1589/4885CYP3A4 637/4885CYP2C9 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.